特邀报告：Transcriptional and functional landscape of circular RNA in cancer | 何厚胜教授
讲座信息
- 主讲嘉宾：何厚胜 教 授 (加拿大多伦多)
- 主持嘉宾：胡璐璐 研究院 (梧桐岛研究员/复旦大学)
- 汇报时间：7月10日 (星期五） 14:30
- 汇报地点：上海市浦东新区张江路88号R01栋219室
讲座简介
Circular RNAs (circRNAs) are a widespread and functionally diverse class of noncoding RNAs with tissue-specific expression and emerging roles in cancer. Using ultra-deep total RNA-seq of 500 patient tumors, we uncovered extensive circRNA production, averaging over 7,000 circRNAs per tumor, correlated with disease progression. A genome-wide functional screen targeting 9,688 clinically relevant circRNAs across seven major cancer types identified ~14% as essential for cell proliferation, with most acting independently of their linear counterparts. While a subset of circRNAs serves as shared regulators across cancer types, the majority exhibit cancer type-specific functions. In prostate cancer, circCSNK1G3 promotes growth via miR-181 interaction, whereas in breast cancer, circNSD1 acts as a tumor suppressor by inhibiting autophagy and oxidative stress through SQSTM1/p62. In neuroendocrine prostate cancer (NEPC) and small cell lung cancer (SCLC), circRMST functions as a lineage regulator, essential for ASCL1 expression and tumor growth via interactions with SOX2 and NKX2-1, and is detectable in liquid biopsies of NEPC and SCLC patients. These findings underscore the critical and distinct roles of circRNAs in tumorigenesis and support the adoption of total RNA-seq and functional genomics to map circRNA-regulatory networks. We further provide FunCirc, an online resource cataloging functional oncogenic circRNAs across cancer types to facilitate biomarker and therapeutic discovery.
汇报人简介
Dr. He’s laboratory studies how RNA programs enable cancer cells to grow, adapt, and resist treatment. By identifying cancer-specific vulnerabilities directly from patient tumours, his team is developing RNA-based therapeutic strategies, including cancer vaccines and other RNA medicines. He also leads the RNA Medicine Core (https://www.pmrnamed.ca/) at Princess Margaret Cancer Centre, which supports the translation of these discoveries into more precise and effective treatments for patients. Dr. He has authored more than 140 publications in high-profile journals, including Nature, Cell, Nature Genetics, and Cancer Cell. The translational research from his laboratory has led to clinical trial applications, patents, and startup company formation. His contributions have been recognized through several major distinctions, including the 2026 AACR Award for Outstanding Achievement in Basic Cancer Research and a Tier 1 Canada Research Chair in RNA Medicine.
报告流程
- PART 01 学术汇报
- PART 02 问答环节
- PART 03 茶歇